Prescient Therapeutics bolsters board with appointment of experienced US-based pharma executive
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has fielded more promising results from its PTX-100 T Cell...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for...
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater...
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.